Atlanta WOW Practice Exam

The reported rate of adverse events for Moxeza, an ophthalmic antibiotic indicated for the treatment of bacterial conjunctivitis, is primarily documented in clinical studies and product information. The 1-2% range reflects the findings from these studies, indicating that in clinical trials, a small proportion of patients experienced adverse effects when using Moxeza. This low rate of adverse events is significant as it suggests the medication is generally well-tolerated while still being effective for its intended use.

While other rates may be plausible based on varying data sets or different clinical contexts, the specific range of 1-2% is supported by the manufacturer and clinical trial results, making it the most accurate choice among the options provided. This data reinforces Moxeza’s safety profile in the context of its application.